In a global phase 2 clinical study, supplemental recombinant human (rh) IGF-1/rhIGF binding protein-3 (rhIGF-1) reduced BPD and IVH severity in extremely preterm infants (18). This evidence concerns the gene IGF1 and bronchopulmonary dysplasia.